Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403049 · ClinicalTrials.gov registry record · Phase 1
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
A Phase 1 study of Cancer and Pancreatic Cancer, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT03403049: Completed Phase 1 study of Cancer and Pancreatic Cancer, sponsored by Albert Einstein College of Medicine.
NCT03403049 is a Phase 1 study of Cancer and Pancreatic Cancer that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 14 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03403049, a Phase 1 study of Cancer and Pancreatic Cancer, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
Primary Outcome
Any CTCAE v. 4.03 non-hematologic adverse event of grade 3 or higher or any hematologic adverse event of grade 4 or higher, occurring within 90 days of the start of radiotherapy and deemed to be related to carbon ion radiotherapy.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Gemcitabine + Cisplatin
- RADIATION Carbon Ion
- DRUG Gemcitabine + Capecitabine
- DRUG Gemcitabine + Erlotinib
Study Locations (2)
New York
- Albert Einstein College of Medicine - The Bronx
Shanghai Municipality
- Shanghai Proton and Heavy Ion Center - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 1 |
What the finished NCT03403049 record still lists
NCT03403049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT03403049 reports a single indexed study location in New York, Shanghai Municipality.
Frequently Asked Questions
What is clinical trial NCT03403049 about?
NCT03403049 is a clinical study titled "Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer". This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
What is the current status of trial NCT03403049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-04-01. Estimated completion is 2019-07-09.
What conditions does trial NCT03403049 study?
This clinical trial studies the following conditions: Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT03403049?
The interventions under investigation include: Gemcitabine (DRUG), Gemcitabine + Cisplatin (DRUG), Carbon Ion (RADIATION), Gemcitabine + Capecitabine (DRUG), Gemcitabine + Erlotinib (DRUG).
Who is sponsoring clinical trial NCT03403049?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03403049 being conducted?
This trial has 2 study locations across New York, Shanghai Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03403049's enrollment target sits among peer trials
14 591st of 615 higher than 25 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy